Jason Silvers

CIK: 0002109011

Transaction Breakdown

Open Market Buys (P)3 (60.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

GENB

Generate Biomedicines, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

GENB
Generate Biomedicines, Inc.
Mar 2, 2026
Purchase(P)
Indirect
500 shares at avg. $16.00$8K
GENB
Generate Biomedicines, Inc.
Mar 2, 2026
Purchase(P)
Indirect
500 shares at avg. $16.00$8K
GENB
Generate Biomedicines, Inc.
Mar 2, 2026
Purchase(P)
Indirect
1K shares at avg. $16.00$16K
GENB
Generate Biomedicines, Inc.
Feb 26, 2026
Award(A)
Stock Option (Right to Buy)
Direct
295.6K shares-
GENB
Generate Biomedicines, Inc.
Feb 26, 2026
Award(A)
Stock Option (Right to Buy)
Direct
274.5K shares-

		Type	Shares	Price		Ownership
Mar 2, 2026	GENB Generate Biomedicines, Inc.	Purchase(P)	500	$16.00	$8,000	Indirect
Mar 2, 2026	GENB Generate Biomedicines, Inc.	Purchase(P)	500	$16.00	$8,000	Indirect
Mar 2, 2026	GENB Generate Biomedicines, Inc.	Purchase(P)	1,000	$16.00	$16,000	Indirect
Feb 26, 2026	GENB Generate Biomedicines, Inc.	Award(A) Stock Option (Right to Buy)	295,608	-	-	Direct
Feb 26, 2026	GENB Generate Biomedicines, Inc.	Award(A) Stock Option (Right to Buy)	274,493	-	-	Direct

1-5 of 5 transactions

About Silvers Jason

Silvers Jason (SEC CIK 0002109011) files insider reports with the SEC as President & CFO of Generate Biomedicines, Inc. (GENB).

Signal8 holds 2 ownership filings by Silvers Jason (1 Form 3, 1 Form 4), filed between Feb 26, 2026 and Mar 2, 2026. Those filings report 5 transactions, from Feb 26, 2026 to Mar 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Silvers Jason's filings is in SOMERVILLE, MA.

Recent filings by Silvers Jason

Mar 2, 2026: Open-market purchases of GENB shares (3 lines, Form 4, code P).
Feb 26, 2026: Grants or awards of GENB derivative securities (2 lines, Form 4, code A).

Other insiders filing for Generate Biomedicines, Inc. (GENB)

ARNOLD FRANCES, Director
Pioneering Medicines 02, LLC, 10% Owner
Nally Michael, Chief Executive Officer
Vessey Rupert, Director
Grous Beth, Chief People Officer
Lee Laurie Anne, Chief Medical Officer

How to read Form 4 transaction codes